期刊
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
卷 363, 期 2, 页码 185-190出版社
ELSEVIER SCIENCE INC
关键词
Methotrexate; Rheumatoid arthritis; Dialysis; Pancytopenia
资金
- National Natural Science Foundation of China [81860139]
- Zunyi Medical University [2017.08]
- Science and Technology Department of Guizhou Province [LKZ (2012) 27]
Methotrexate is an effective medication for treating rheumatoid arthritis and other diseases, but it can cause severe pancytopenia complications in dialysis patients. Supportive treatment and blood purification can help patients recover.
Methotrexate (MTX) is an effective medication in the treatment of rheumatoid arthritis (RA), other rheumatic diseases and various solid tumors. However, its side effects, including gastrointestinal discomfort, oral ulcers, and especially bone marrow suppression, could be fatal and require special attention, particularly in patients with renal failure. We present two hemodialysis patients with RA who presented with a complication of severe pancytopenia after treatment with MTX. After receiving various supportive and blood purification treatments, both patients recovered. We reviewed twenty-four pancytopenia patients on dialysis associated with methotrexate. Among these patients, high morbidity and mortality were observed, indicating that MTX should be used cautiously in the absence of alternatives in such a population. Compared with the patients who recovered, the deceased patients showed a lower level of leukocytes. Which dialysis method might be the best choice is unclear. The mode of renal replacement therapy can be chosen according to the actual situation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据